Ask AI
ProCE Banner Activity

Bringing Bispecific Therapy Home: Best Practices for Transitioning Multiple Myeloma Patients from Academic to Community Care

Clinical Thought

Bispecific antibodies have transformed outcomes for heavily pretreated multiple myeloma, but their safe delivery depends on strong coordination between academic centers and community oncology practices. Explore practical strategies for structured transitions, adverse event management, and communication models that enable high-quality care closer to home.

Released: December 24, 2025

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity's target audience includes community hematologists/oncologists and other healthcare professionals responsible for the care and treatment of patients with relapsed refractory multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the criteria for R/R MM diagnosis and the subsequent process for timely initiation of care, emphasizing the importance of early intervention

  • Demonstrate proficiency in the handling, administration, and transitioning care of BsAbs from academic to community settings, ensuring continuity of care

  • Evaluate the available clinical data on BCMA BsAbs, interpreting insights into their efficacy, appropriate dosing, and adverse events (AEs) profiles for informed decision-making

  • Identify the key risk factors associated with treatment-specific AEs related to BsAbs and formulate evidence-based strategies for timely identification and effective management

  • Advocate for equity in R/R MM treatment by recognizing disparities in care, highlighting experiences with BsAbs, and promoting strategies that ensure equitable access to treatment for diverse and underrepresented patient populations

Disclosure

Primary Author

Caitlin Costello, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Janssen, Kite; researcher: AstraZeneca, Bristol Myers Squibb, Janssen, Kite, Poseida, Takeda.